OSPREY trial: randomized, active-controlled, phase II study to evaluate safety and efficacy of RTH258, a humanized single-chain anti-VEGF antibody fragment, in patients with neovascular AMD
Year: 2015
Type: article
Language: English
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W949793921
